About
Galimedix develops small molecule therapies to treat neurodegenerative diseases affecting the eye and brain, including dry age-related macular degeneration, glaucoma, and Alzheimer's disease, with its lead candidate GAL-101 currently in Phase 2 clinical trials.
Explore Galimedix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.